56
2026 may prove a pivotal year for obesity. GLP-1 receptor agonists have revolutionised obesity management over the past 10 years. Mounting evidence has established their benefits across many cardiometabolic and obesity-related conditions and the global weight-loss medications market is predicted to reach US$150 billion by 2035. More than a billion people live with obesity, with the burden rising rapidly in low-income and middle-income countries. High costs, limited production capacity, and supply-chain constraints have resulted in persistent inequitable access to GLP-1 receptor agonists.
